To control the costs of prescription drugs, Germany combines immediate access to innovative drugs with price controls. The system assesses scientific evidence on the value of new drugs to determine adequate price ranges. While price controls are supervised by the government, the system is administered by public sickness funds, an independent scientific institute, and stakeholders. The advantages and limits of the German experience will be discussed, including lessons for U.S. health reforms.
This event is free and open to the public. Participants are welcome to bring their own lunch.